Healthcare analytics · Tempus AI, Inc.
Tempus AI
Precision-medicine company combining genomic sequencing and clinical data with AI analytics for oncology and other diseases.
Tempus AI runs molecular and genomic testing laboratories and pairs that lab data with clinical records, imaging and other structured and unstructured data to build large multimodal datasets, primarily in oncology but expanding into other therapeutic areas. It sells to two main audiences: clinicians, who use its sequencing and AI-driven decision-support tools to help match patients to targeted therapies and clinical trials, and pharmaceutical and life-sciences companies, who license de-identified data derived from its testing volume for drug development and real-world evidence. This combination of an active diagnostics business with a data-licensing business distinguishes it from pure data aggregators. It is a publicly traded company (Nasdaq: TEM) and handles protected patient data under HIPAA, de-identifying data used for research and commercial licensing.
At a glance
| Vendor | Tempus AI, Inc. |
|---|---|
| Pricing model | Quote only |
| Free tier | No |
| Deployment | Cloud |
| Open source | No |
| Best for | Oncology clinicians and pharma or life-sciences teams needing genomic testing paired with real-world data analytics. |
Pricing
Genomic testing is billed per test, often through insurance; data-licensing and AI platform access are sold on enterprise contracts. Pricing is not published.
Pricing has not been verified yet — see the vendor's site.
Features
- Genomic and molecular sequencing laboratory services
- AI-driven treatment-matching decision support for oncology
- Multimodal data combining genomic, clinical and imaging records
- De-identified real-world data licensing for pharma
- Clinical trial matching
- Expansion into non-oncology therapeutic areas
Profile last reviewed September 21, 2026